Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
- PMID: 11190905
- DOI: 10.1177/107602960100700102
Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
Abstract
Several hemostatic and vascular endothelial cell markers were measured in 39 patients with thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) and in 20 healthy volunteers to examine the relationship between the occurrence of hemostatic abnormality or vascular endothelial cell injury and patient outcome. The plasma levels of von Willebrand factor, tissue plasminogen activator (TPA), plasminogen activator inhibitor (PAI-1), and the TPA-PAI-1 complex were significantly increased in TTP/HUS patients; however, the levels of these markers were not significantly different between TTP/HUS patients who survived and those who died, suggesting that these markers might not be directly related to outcome. The plasma levels of soluble granule membrane protein (GMP)-140 were significantly higher in TTP/HUS patients than in healthy volunteers, suggesting that platelets and vascular endothelial cells are activated or injured in TTP/HUS. There was no significant difference in GMP-140 levels between TTP/HUS patients with good and poor prognoses; this may be owing to the release of GMP-140 from platelets. The plasma thrombomodulin (TM) levels in TTP/HUS patients were significantly higher than in healthy volunteers; the plasma TM levels were significantly higher in patients who died than in patients who survived. These findings showed that TM levels reflect the outcome and that the outcome of TTP/HUS depends on the presence vascular endothelial cell injury. The plasma protein C and antithrombin levels were markedly reduced in TTP/HUS patients who died compared with those who survived. These findings suggest that reduced plasma antithrombin and protein C may be useful markers of systemic vascular endothelial injury. In conclusion, the results of this study showed that the outcome of TTP/HUS is related to vascular endothelial cell injury and that plasma TM, antithrombin, and protein C levels may be useful markers of systemic vascular endothelial cell injury.
Comment in
-
Increased soluble thrombomodulin does not always indicate endothelial injury.Clin Appl Thromb Hemost. 2002 Jan;8(1):87-9. doi: 10.1177/107602960200800113. Clin Appl Thromb Hemost. 2002. PMID: 11991246 No abstract available.
Similar articles
-
Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries.Am J Hematol. 1998 Jul;58(3):189-94. doi: 10.1002/(sici)1096-8652(199807)58:3<189::aid-ajh5>3.0.co;2-n. Am J Hematol. 1998. PMID: 9662269
-
Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).Am J Hematol. 1996 Dec;53(4):213-20. doi: 10.1002/(SICI)1096-8652(199612)53:4<213::AID-AJH1>3.0.CO;2-0. Am J Hematol. 1996. PMID: 8948657
-
Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.Am J Hematol. 1993 Oct;44(2):101-5. doi: 10.1002/ajh.2830440206. Am J Hematol. 1993. PMID: 8266913
-
Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.Best Pract Res Clin Haematol. 2001 Jun;14(2):437-54. doi: 10.1053/beha.2001.0142. Best Pract Res Clin Haematol. 2001. PMID: 11686108 Review.
-
Pathophysiology and treatment of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).Int J Hematol. 2000 Jun;71(4):320-7. Int J Hematol. 2000. PMID: 10905050 Review.
Cited by
-
Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.TH Open. 2022 Jul 11;6(3):e194-e212. doi: 10.1055/a-1801-2055. eCollection 2022 Jul. TH Open. 2022. PMID: 36046203 Free PMC article. Review.
-
Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura.Medicine (Baltimore). 2016 Jun;95(24):e3712. doi: 10.1097/MD.0000000000003712. Medicine (Baltimore). 2016. PMID: 27310951 Free PMC article.
-
The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.Clin Appl Thromb Hemost. 2018 Sep;24(6):920-927. doi: 10.1177/1076029617736382. Epub 2017 Nov 12. Clin Appl Thromb Hemost. 2018. PMID: 29130325 Free PMC article. Clinical Trial.
-
C-type lectin family XIV members and angiogenesis.Oncol Lett. 2019 Oct;18(4):3954-3962. doi: 10.3892/ol.2019.10760. Epub 2019 Aug 16. Oncol Lett. 2019. PMID: 31579078 Free PMC article. Review.
-
Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection.J Clin Med. 2023 Nov 19;12(22):7174. doi: 10.3390/jcm12227174. J Clin Med. 2023. PMID: 38002786 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous